

DOCKET NO.: 279431US0PCT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN RE APPLICATION OF:

GROUP: 1612

Tatsuo KIMURA, et al.

SERIAL NO: 10/553,120

EXAMINER: HUANG, G.

FILED: October 14, 2005


FOR: PREVENTIVE/REMEDY FOR RETINAL NERVE DISEASES CONTAINING  
ALKYL ETHER DERIVATIVES OR SALTS THEREOF

**RESTRICTION RESPONSE**


COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

Sir:

In response to the Restriction Requirement dated May 9, 2008, Applicants elect, with traverse, Group I, Claims 1–4 (in part), for examination. Applicants also provisionally elect, for examination purposes, the specie where:



is (A)



(A)

,

$R^1$  and  $R^2$  are hydrogen atoms,  $R^3$  is OH, m is 2, n is 3, and p is 1 (readable on at least Claims 1–4). Specifically, said compound is 1-[3-(2-(1-benzothiophen-5-yl)ethoxy)propyl]-3-azetidinol.

**Remarks/Arguments** begin on page 2 of this paper.